Rabbit Recombinant Monoclonal Somatostatin Receptor 2 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.
Somatostatin receptor type 2, SS-2-R, SS2-R, SS2R, SST2, SRIF-1, SSTR2
Rabbit Recombinant Monoclonal Somatostatin Receptor 2 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
The specificity of this antibody was demonstrated in a Somatostatin Receptor 2-deficient mouse model. Refer to Fischer et al.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
The somatostatin receptor 2 (SSTR2) also known as SS2R serves as a G protein-coupled receptor with a molecular mass of approximately 40-60 kDa. SSTR2 specifically binds somatostatin a peptide hormone that regulates the endocrine system neurotransmission and cell proliferation via interaction with various somatostatin receptors. Scientists find SSTR2 expressed in high levels in the pituitary gland central nervous system gastrointestinal tract and pancreatic cells.
Somatostatin receptor 2 mediates the inhibitory effects of somatostatin on cell growth and the release of other hormones. It functions as part of the receptor complex modulating intracellular signaling pathways. SSTR2 often interacts closely with other molecules like G proteins to inhibit adenylyl cyclase reducing cyclic AMP (cAMP) levels and influencing diverse cellular responses. The receptor's ability to influence such processes emphasizes its role in maintaining cellular and systemic homeostasis.
Somatostatin receptor 2 plays an important role in the inhibitory signaling pathways related to growth hormone regulation and neurotransmitter release. SSTR2 actively participates in the somatostatin signaling pathway intimately interacting with proteins such as adenylate cyclase and phospholipase C. Another important pathway includes the regulation of the MAPK pathway serving to modulate cell proliferation and survival reiterating its regulatory function within endocrine signaling and cellular communication.
Somatostatin receptor 2 demonstrates significant involvement in neuroendocrine tumors and acromegaly. The overexpression of SSTR2 in neuroendocrine tumors provides a valuable target for diagnostic imaging and therapeutic interventions using somatostatin analogs. In acromegaly where excess growth hormone production occurs SSTR2's modulation of growth hormone release becomes important; it often works alongside growth hormone receptors and IGF-1 to limit abnormal growth. Therefore the receptor's targeting offers therapeutic potential and advances disease understanding.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com